MORAb-050 is an investigational, fully human, IgM monoclonal antibody that targets the ganglioside GM3, which resides on a majority of melanoma tumor cells and other tumors of neural crest origin. MORAb-050 is currently undergoing preclinical evaluation to support an Investigational New Drug application. MORAb-050 will be investigated in patients with GM3-positive metastatic melanoma.
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.